Skip to main content
main-content

Vivek Subbiah

Vivek Subbiah, M.D., is an associate professor in the Investigational Cancer Therapeutics department (a Phase 1 program). He is the Center Clinical Medical Director of the Clinical Center for Targeted Therapy, Cancer Medicine division, at The University of Texas MD Anderson Cancer Center.

Latest contributions from Vivek Subbiah

15-05-2020 | FDA | News

Selpercatinib receives FDA nod

Read more about this approval here

09-07-2019 | Non-small-cell lung cancer | News

Vemurafenib monotherapy has potential for BRAF-mutated NSCLC

Single-agent vemurafenib has demonstrated promising antitumor activity against non-small-cell lung cancer harboring BRAF V600E mutations in the VE-BASKET trial.

30-04-2018 | RET inhibitors | News

More evidence for selective RET inhibition in RET-altered cancers

A report of two patients with advanced tumors harboring alterations in the RET gene who responded to treatment with the selective inhibitor LOXO-292 highlights that the clinical actionability of RET mutations, say researchers.

19-04-2018 | Medullary thyroid carcinoma | News

Targeted inhibitor shows potential for RET-altered solid tumors

A selective inhibitor of the receptor tyrosine kinase RET could benefit patients with tumors harboring alterations in the oncogene, suggest early results presented at the American Association for Cancer Research Annual Meeting 2018.

Image Credits